New hope for tough lymphomas? daily pill trial launches
NCT ID NCT06300528
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This phase II trial tests the drug pemigatinib (Pemazyre) in 27 adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell and marginal zone lymphoma. Participants take one pill daily in 28-day cycles. The main goal is to see if the drug can shrink tumors after at least two prior treatments have failed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pemigatinib (Pemazyre), a daily oral drug
- What this could lead to
- If it works, this could offer a new treatment option for people with certain lymphomas that have not responded to other therapies.
- What could go wrong
- This is a small, early-phase trial (27 people) with no control group, so results may not be definitive. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Can a cancer drug reboot the immune system after a stem cell transplant?